


Desonide

Cat. No.:	HY-B0248		
CAS No.:	638-94-8		
Molecular Formula:	C ₂₄ H ₃₂ O ₆		
Molecular Weight:	416.51		
Target:	Glucocorticoid Receptor		
Pathway:	Immunology/Inflammation; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (240.09 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.4009 mL	12.0045 mL	24.0090 mL
	5 mM	0.4802 mL	2.4009 mL	4.8018 mL
	10 mM	0.2401 mL	1.2005 mL	2.4009 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 3.25 mg/mL (7.80 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. Target: Glucocorticoid Receptor. Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses [1]. Desonide induced significant colorimetric improvement compared with placebo. A good to excellent response was achieved in 30% for desonide, and 6% for placebo. Decreased pigmentation in the desonide-treated axillae was associated with recovery of disruption at the basal membrane. Desonide showed depigmenting properties in women with axillary hyperpigmentation [2]. Given the favorable safety profile of all other desonide preparations and their

utility as a low potency corticosteroid, desonide foam promises to be a useful addition to the armamentarium, when other desonide vehicles might be less acceptable [3].

CUSTOMER VALIDATION

- Drug Test Anal. 2020 Aug 27.
- Queen Mary University of London. 2018 Feb.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Kahane, N., C. Gelbard, and A. Hebert, Desonide: a review of formulations, efficacy and safety. *Expert Opin Investig Drugs*, 2008. 17(7): p. 1097-104.
- [2]. Castanedo-Cazares, J.P., et al., Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. *Clin Cosmet Investig Dermatol*, 2013. 6: p. 29-36.
- [3]. Parish, D. and N. Scheinfeld, Desonide foam: a review. *Drugs Today (Barc)*, 2008. 44(1): p. 55-62.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA